Our results show that even in the poorly mutated and immunogenic SB28 GBM model, there is still evidence for immune activation, with IFN-γ measured in the tumor (data not shown) and an IFN-γ response gene signature detected ex vivo. This evidence concerns the gene IFNG and glioblastoma.